LUPKYNIS (Voclosporin) in combination with belimumab, obinutuzumab or anifrolumab - (PRESERVE)

July 6, 2026: Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced initiation of PRESERVE, a Phase 4, multicenter study evaluating LUPKYNIS (voclosporin) in combination with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis (listed on ClinicalTrials.gov). The trial plans to enroll ~150 patients across ~50 U.S. sites. The primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months. Aurinia stated LUPKYNIS is the only FDA-approved oral therapy for lupus nephritis and has shown a statistically significant increase in CRR after 6 months of therapy. The press release notes the combination rationale targets non-redundant pathways (LUPKYNIS: podocyte stabilization/T-cell inhibition; belimumab/obinutuzumab: B-cell inhibition; anifrolumab: type 1 interferon signaling blockade). The company also noted it is developing aritinercept, a dual BAFF/APRIL inhibitor for potential treatment of autoimmune diseases.